Suppl. Figure S1 from Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non–Small Cell Lung Cancer

Abstract

&lt;p&gt;The crizotinib-resistant NSCLC from Case #1 retains the MET exon 14 skipping mutation in association with persistent MET protein expression but lacks genomic MET amplification.&lt;/p&gt;